Gyre Therapeutics 2026 shareholder votes approved
Gyre Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Gyre Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders. There were 96,994,001 shares of common stock entitled to vote as of the April 16, 2026 record date.
Stockholders elected Class II directors David M. Epstein, Ph.D. and Dan Weng, M.D. to serve until the 2029 annual meeting. A non-binding advisory vote approved executive compensation. Stockholders also ratified Grant Thornton Zhitong Certified Public Accountants LLP as independent auditor for 2026 and approved issuing common stock upon conversion of Series B Convertible Preferred Stock in accordance with Nasdaq Listing Rule 5635(a).
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 96,994,001 shares
Votes for David M. Epstein: 70,160,332 votes
Votes for Dan Weng: 70,483,425 votes
+3 more
6 metrics
Shares entitled to vote
96,994,001 shares
Common stock entitled to vote as of April 16, 2026 record date
Votes for David M. Epstein
70,160,332 votes
Election as Class II director at 2026 annual meeting
Votes for Dan Weng
70,483,425 votes
Election as Class II director at 2026 annual meeting
Say-on-pay support
70,478,374 votes for
Non-binding advisory vote on executive compensation
Auditor ratification votes for
72,487,596 votes
Ratification of Grant Thornton Zhitong for year ending December 31, 2026
Series B conversion approval votes for
70,497,125 votes
Approval of issuing common stock upon conversion of Series B Convertible Preferred Stock
Key Terms
non-binding, advisory basis, Broker Non-Votes, Nasdaq Listing Rule 5635(a), Series B Convertible Preferred Stock, +1 more
5 terms
non-binding, advisory basis financial
"The compensation of the Company’s named executive officers was approved, on a non-binding, advisory basis, as follows"
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.
Broker Non-Votes financial
"Votes For | Votes Withheld | Broker Non-Votes • David M. Epstein, Ph.D."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Nasdaq Listing Rule 5635(a) regulatory
"was approved, in accordance with Nasdaq Listing Rule 5635(a), as follows"
Series B Convertible Preferred Stock financial
"upon conversion of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share, was approved"
Series B convertible preferred stock is a class of shares sold during a later-stage private financing that combines features of a loan and common stock: it usually pays priority dividends or has a priority claim if the company is sold, and it can be converted into common shares under predefined rules. Investors care because these shares affect ownership stakes and payout order—like having a reserved place in line and a ticket that can turn into regular ownership—so they influence potential returns and dilution for other shareholders.
independent registered public accounting firm financial
"as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Gyre Therapeutics (GYRE) stockholders vote on at the 2026 annual meeting?
Stockholders voted on director elections, executive pay, auditor ratification, and approval of common stock issuance upon conversion of Series B Convertible Preferred Stock. All proposals received sufficient support based on the reported final voting results.
Which directors were elected at Gyre Therapeutics (GYRE) 2026 annual meeting?
Stockholders elected Class II directors David M. Epstein, Ph.D. and Dan Weng, M.D. Both will serve until the 2029 annual meeting, based on strong support in the reported vote tallies and limited withheld votes.
How did Gyre Therapeutics (GYRE) stockholders vote on executive compensation?
Stockholders approved the compensation of named executive officers on a non-binding advisory basis. The proposal received 70,478,374 votes for, 34,907 against, 1,160 abstentions, and 1,985,197 broker non-votes, indicating broad support among votes cast.
Which auditor did Gyre Therapeutics (GYRE) stockholders ratify for 2026?
Stockholders ratified Grant Thornton Zhitong Certified Public Accountants LLP as independent registered public accounting firm for the year ending December 31, 2026. The auditor ratification proposal received 72,487,596 votes for, 11,626 against, and 416 abstentions, with no broker non-votes reported.
What did Gyre Therapeutics (GYRE) approve regarding Series B Convertible Preferred Stock?
Stockholders approved issuing common stock upon conversion of the company’s Series B Convertible Preferred Stock. The proposal, required under Nasdaq Listing Rule 5635(a), received 70,497,125 votes for, 16,031 against, 1,285 abstentions, and 1,985,197 broker non-votes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates